New combo therapy shows promise for Tough-to-Treat cervical cancer
NCT ID NCT03614949
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study tests whether adding targeted radiation (SBRT) to an immunotherapy drug (atezolizumab) can shrink tumors better than the drug alone in people with cervical cancer that has come back or spread. About 21 adults with advanced cervical, vaginal, or vulvar cancer are participating. The goal is to see if the combination improves the number of patients whose tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Ohio State University - OSUMC - Wexner Medical Center
Hilliard, Ohio, 43026, United States
Conditions
Explore the condition pages connected to this study.